Health Catalyst (NASDAQ:HCAT – Free Report) had its target price decreased by Wells Fargo & Company from $14.00 to $13.00 in a research report report published on Friday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.
Other analysts have also issued reports about the company. Cantor Fitzgerald reissued an overweight rating and set a $16.00 price target on shares of Health Catalyst in a research note on Wednesday, April 10th. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $12.00 to $11.00 and set a buy rating for the company in a research report on Friday, February 23rd. Evercore ISI cut their price target on shares of Health Catalyst from $11.00 to $10.00 and set an outperform rating on the stock in a report on Friday, February 23rd. KeyCorp reiterated a sector weight rating on shares of Health Catalyst in a report on Wednesday, April 10th. Finally, Piper Sandler reiterated an overweight rating and set a $15.00 price target (down previously from $17.00) on shares of Health Catalyst in a report on Friday, February 23rd. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and an average target price of $12.18.
Check Out Our Latest Research Report on Health Catalyst
Health Catalyst Trading Up 5.9 %
Shares of Health Catalyst stock opened at $6.79 on Friday. The firm has a market capitalization of $400.81 million, a PE ratio of -3.67 and a beta of 1.32. The company has a current ratio of 4.42, a quick ratio of 4.42 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $6.99 and its 200 day moving average is $8.14. Health Catalyst has a 1 year low of $5.45 and a 1 year high of $14.37.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.68%. The firm had revenue of $75.08 million for the quarter, compared to analysts’ expectations of $73.67 million. Equities research analysts forecast that Health Catalyst will post -0.47 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Health Catalyst
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC bought a new stake in Health Catalyst in the fourth quarter valued at $108,000. Tower Research Capital LLC TRC increased its stake in Health Catalyst by 285.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,018 shares of the company’s stock valued at $111,000 after purchasing an additional 8,900 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in Health Catalyst in the third quarter valued at $114,000. MQS Management LLC bought a new stake in Health Catalyst in the third quarter valued at $116,000. Finally, Versor Investments LP bought a new stake in Health Catalyst in the third quarter valued at $117,000. Institutional investors and hedge funds own 85.00% of the company’s stock.
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Featured Articles
Receive News & Ratings for Health Catalyst Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Health Catalyst and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
